SAB Biotherapeutics (SABS) Stock Forecast, Price Target & Predictions
SABS Stock Forecast
SAB Biotherapeutics stock forecast is as follows: an average price target of $5.67 (represents a 40.35% upside from SABS’s last price of $4.04) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
SABS Price Target
SABS Analyst Ratings
SAB Biotherapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 07, 2024 | Kumaraguru Raja | Loop Capital Markets | $8.00 | $2.84 | 181.69% | 98.02% |
Apr 02, 2024 | Edward White | H.C. Wainwright | $6.00 | $4.29 | 39.86% | 48.51% |
Aug 11, 2022 | - | Chardan Capital | $3.00 | $1.12 | 167.86% | -25.74% |
SAB Biotherapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $7.00 |
Last Closing Price | $4.04 | $4.04 | $4.04 |
Upside/Downside | -100.00% | -100.00% | 73.27% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 09, 2024 | Craig-Hallum | - | Buy | Initialise |
Aug 27, 2024 | Oppenheimer | - | Outperform | Initialise |
Jun 07, 2024 | Brookline Capital | - | Buy | Initialise |
Apr 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Aug 11, 2022 | Chardan Capital | Buy | Buy | Hold |
May 13, 2022 | Chardan Capital | Buy | Buy | Hold |
SAB Biotherapeutics Financial Forecast
SAB Biotherapeutics Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | $1.27M | $85.52K | $581.10K | $2.16M | $3.59M | $6.35M | $11.80M | $60.88M | - |
Avg Forecast | $500.00K | $500.00K | $500.00K | $500.00K | $333.33K | $333.33K | $333.33K | $333.33K | $120.00K | $120.00K | $263.14K | $11.97K | $400.00K | $2.54M | $5.90M | $6.85M | $10.80M | $11.47M | $16.90M | $14.40M |
High Forecast | $500.00K | $500.00K | $500.00K | $500.00K | $333.33K | $333.33K | $333.33K | $333.33K | $120.00K | $120.00K | $263.14K | $11.98K | $400.00K | $2.54M | $5.90M | $6.85M | $10.80M | $11.47M | $16.90M | $17.28M |
Low Forecast | $500.00K | $500.00K | $500.00K | $500.00K | $333.33K | $333.33K | $333.33K | $333.33K | $120.00K | $120.00K | $263.14K | $11.95K | $400.00K | $2.54M | $5.90M | $6.85M | $10.80M | $11.47M | $16.90M | $11.52M |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 7 | 5 | 11 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 105.91% | 0.21% | 0.23% | 0.37% | 0.52% | 0.59% | 1.03% | 3.60% | - |
SAB Biotherapeutics EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 7 | 5 | 11 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-4.23M | $-6.48M | $-6.42M | $-7.80M | $-6.88M | $-5.75M | $-6.02M | $-11.52M | $-337.35K |
Avg Forecast | $-280.98K | $-280.98K | $-280.98K | $-280.98K | $-187.32K | $-187.32K | $-187.32K | $-187.32K | $-67.43K | $-67.43K | $-147.87K | $-6.72K | $-224.78K | $-1.43M | $-3.32M | $-3.85M | $-6.07M | $-6.44M | $-9.50M | $-539.75K |
High Forecast | $-280.98K | $-280.98K | $-280.98K | $-280.98K | $-187.32K | $-187.32K | $-187.32K | $-187.32K | $-67.43K | $-67.43K | $-147.87K | $-6.71K | $-224.78K | $-1.43M | $-3.32M | $-3.85M | $-6.07M | $-6.44M | $-9.50M | $-431.80K |
Low Forecast | $-280.98K | $-280.98K | $-280.98K | $-280.98K | $-187.32K | $-187.32K | $-187.32K | $-187.32K | $-67.43K | $-67.43K | $-147.87K | $-6.73K | $-224.78K | $-1.43M | $-3.32M | $-3.85M | $-6.07M | $-6.44M | $-9.50M | $-647.70K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 628.48% | 28.81% | 4.50% | 2.35% | 1.79% | 0.95% | 0.93% | 1.21% | 0.63% |
SAB Biotherapeutics Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 7 | 5 | 11 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | $-5.10M | $-6.88M | $-7.40M | $-7.87M | $-6.34M | $-4.78M | $985.86K | $-17.88M | $-326.11K |
Avg Forecast | $-8.42M | $-8.14M | $-7.87M | $-7.59M | $-6.45M | $-6.39M | $-6.39M | $-8.58M | $-10.66M | $-10.24M | $-10.61M | $-10.80M | $-12.96M | $-10.49M | $-9.02M | $-13.27M | $-12.03M | $-13.27M | $-8.02M | $-529.33K |
High Forecast | $-8.42M | $-8.14M | $-7.87M | $-7.59M | $-6.45M | $-6.39M | $-6.39M | $-8.58M | $-10.66M | $-10.14M | $-10.61M | $-10.80M | $-12.96M | $-10.49M | $-9.02M | $-13.27M | $-12.03M | $-13.27M | $-8.02M | $-423.46K |
Low Forecast | $-8.42M | $-8.14M | $-7.87M | $-7.59M | $-6.45M | $-6.39M | $-6.39M | $-8.58M | $-10.66M | $-10.43M | $-10.61M | $-10.80M | $-12.96M | $-10.49M | $-9.02M | $-13.27M | $-12.03M | $-13.27M | $-8.02M | $-635.19K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.47% | 0.53% | 0.71% | 0.87% | 0.48% | 0.40% | -0.07% | 2.23% | 0.62% |
SAB Biotherapeutics SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 7 | 5 | 11 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | $2.57M | $2.90M | $3.45M | $2.88M | $4.04M | $4.31M | $5.19M | $17.09M | - |
Avg Forecast | $1.12M | $1.12M | $1.12M | $1.12M | $749.02K | $749.02K | $749.02K | $749.02K | $269.65K | $269.65K | $591.29K | $26.89K | $898.83K | $5.71M | $13.26M | $15.39M | $24.27M | $25.77M | $37.97M | $32.36M |
High Forecast | $1.12M | $1.12M | $1.12M | $1.12M | $749.02K | $749.02K | $749.02K | $749.02K | $269.65K | $269.65K | $591.29K | $26.93K | $898.83K | $5.71M | $13.26M | $15.39M | $24.27M | $25.77M | $37.97M | $38.83M |
Low Forecast | $1.12M | $1.12M | $1.12M | $1.12M | $749.02K | $749.02K | $749.02K | $749.02K | $269.65K | $269.65K | $591.29K | $26.85K | $898.83K | $5.71M | $13.26M | $15.39M | $24.27M | $25.77M | $37.97M | $25.89M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 95.60% | 3.23% | 0.60% | 0.22% | 0.26% | 0.18% | 0.20% | 0.45% | - |
SAB Biotherapeutics EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 7 | 5 | 11 |
EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.10 | $-0.14 | $-0.15 | $-0.18 | $-0.15 | $-0.11 | $0.02 | $-0.41 | $-0.09 |
Avg Forecast | $-0.91 | $-0.88 | $-0.85 | $-0.82 | $-0.70 | $-0.69 | $-0.69 | $-0.93 | $-1.15 | $-1.11 | $-1.15 | $-1.17 | $-1.40 | $-1.13 | $-0.97 | $-1.43 | $-1.30 | $-1.43 | $-0.87 | $1.25 |
High Forecast | $-0.91 | $-0.88 | $-0.85 | $-0.82 | $-0.70 | $-0.69 | $-0.69 | $-0.93 | $-1.15 | $-1.10 | $-1.15 | $-1.17 | $-1.40 | $-1.13 | $-0.97 | $-1.43 | $-1.30 | $-1.43 | $-0.87 | $1.25 |
Low Forecast | $-0.91 | $-0.88 | $-0.85 | $-0.82 | $-0.70 | $-0.69 | $-0.69 | $-0.93 | $-1.15 | $-1.13 | $-1.15 | $-1.17 | $-1.40 | $-1.13 | $-0.97 | $-1.43 | $-1.30 | $-1.43 | $-0.87 | $1.25 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.08% | 0.10% | 0.13% | 0.18% | 0.10% | 0.08% | -0.01% | 0.47% | -0.08% |
SAB Biotherapeutics Peer Comparison by Price Target
SABS Forecast FAQ
Is SAB Biotherapeutics a good buy?
Yes, according to 5 Wall Street analysts, SAB Biotherapeutics (SABS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of SABS's total ratings.
What is SABS's price target?
SAB Biotherapeutics (SABS) average price target is $5.67 with a range of $3 to $8, implying a 40.35% from its last price of $4.04. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will SAB Biotherapeutics stock go up soon?
According to Wall Street analysts' prediction for SABS stock, the company can go up by 40.35% (from the last price of $4.04 to the average price target of $5.67), up by 98.02% based on the highest stock price target, and down by -25.74% based on the lowest stock price target.
Can SAB Biotherapeutics stock reach $6?
SABS's highest twelve months analyst stock price target of $8 supports the claim that SAB Biotherapeutics can reach $6 in the near future.
What are SAB Biotherapeutics's analysts' financial forecasts?
SAB Biotherapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.33M (high $1.33M, low $1.33M), average EBITDA is $-749K (high $-749K, low $-749K), average net income is $-27.796M (high $-27.796M, low $-27.796M), average SG&A $3M (high $3M, low $3M), and average EPS is $-3.003 (high $-3.003, low $-3.003). SABS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2M (high $2M, low $2M), average EBITDA is $-1.124M (high $-1.124M, low $-1.124M), average net income is $-32.022M (high $-32.022M, low $-32.022M), average SG&A $4.49M (high $4.49M, low $4.49M), and average EPS is $-3.46 (high $-3.46, low $-3.46).
Did the SABS's actual financial results beat the analysts' financial forecasts?
Based on SAB Biotherapeutics's last annual report (Dec 2022), the company's revenue was $23.9M, which missed the average analysts forecast of $35.02M by -31.74%. Apple's EBITDA was $-27.159M, beating the average prediction of $-19.679M by 38.01%. The company's net income was $-18.741M, missing the average estimation of $-47.586M by -60.62%. Apple's SG&A was $16.38M, missing the average forecast of $78.69M by -79.18%. Lastly, the company's EPS was $-0.43, missing the average prediction of $-5.142 by -91.64%. In terms of the last quarterly report (Sep 2023), SAB Biotherapeutics's revenue was $1.27M, beating the average analysts' forecast of $11.97K by 10491.35%. The company's EBITDA was $-4.226M, beating the average prediction of $-6.724K by 62748.44%. SAB Biotherapeutics's net income was $-5.102M, missing the average estimation of $-10.798M by -52.75%. The company's SG&A was $2.57M, beating the average forecast of $26.89K by 9460.27%. Lastly, the company's EPS was $-0.0974, missing the average prediction of $-1.167 by -91.65%